Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Current Drug Targets

• Publication date

  2003-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1389450033490939PMID 12866662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Therapy of Postprandial Hyperglycaemia

  2012cited by this paper
• Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth

  2004cited by this paper
• Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes

  2002cited by this paper
• Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.

  2002cited by this paper
• Predisposition to Atherosclerosis by Infections: Role of Endothelial Dysfunction

  2002cited by this paper
• Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study.

  2002cited by this paper
• Inflammation and Atherosclerosis

  2002cited by this paper
• Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

  2002cited by this paper
• Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women

  2002cited by this paper
• The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm

  2002cited by this paper
• Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes.

  2002cited by this paper
• Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women.

  2002cited by this paper
• Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium.

  2002cited by this paper
• Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.

  2002cited by this paper
• The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats.

  2002cited by this paper
• Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus.

  2002cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

  2002cited by this paper
• Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.

  2002cited by this paper
• Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

  2002cited by this paper
• C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.

  2002cited by this paper
• Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

  2002cited by this paper
• Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.

  2002cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus: Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylaminohydrolase

  2002cited by this paper
• Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events

  2002cited by this paper
• Endothelial function: a barometer for cardiovascular risk?

  2002cited by this paper
• Drugs affecting homocysteine metabolism: impact on cardiovascular risk.

  2002cited by this paper
• Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress

  2002cited by this paper
• Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects

  2001cited by this paper
• Serum Homocysteine Levels Are Associated With the Development of (Micro)albuminuria: The Hoorn Study

  2001cited by this paper
• Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels

  2001cited by this paper
• Platelet dysfunction in type 2 diabetes.

  2001cited by this paper
• Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

  2001cited by this paper
• Treatment for the procoagulant state in type 2 diabetes.

  2001cited by this paper
• Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture.

  2001cited by this paper
• Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria.

  2001cited by this paper
• Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study.

  2001cited by this paper
• Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study.

  2001cited by this paper
• C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.

  2001cited by this paper
• Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond.

  2001cited by this paper
• Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

  2001cited by this paper
• The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes.

  2001cited by this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cited by this paper
• Diabetes mellitus: a hypercoagulable state.

  2001cited by this paper
• Weight change and blood coagulability and fibrinolysis in healthy obese women

  2001cited by this paper
• Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence

  2001cited by this paper
• Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.

  2001cited by this paper
• Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes

  2001cited by this paper
• Insulin resistance and cardiovascular disease.

  2001cited by this paper
• Diabetes and endothelial dysfunction: a clinical perspective.

  2001cited by this paper
• Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus

  2001cited by this paper
• Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance.

  2000cited by this paper
• Association between C-reactive protein and features of the metabolic syndrome: a population-based study.

  2000cited by this paper
• Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.

  2000cited by this paper
• Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

  2000cited by this paper
• Infections, inflammation, and the risk of coronary heart disease.

  2000cited by this paper
• Nitric oxide and vascular responses in Type I diabetes

  2000cited by this paper
• Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

  2000cited by this paper
• Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.

  2000cited by this paper
• Plasma homocysteine and all-cause mortality in diabetes.

  1999cited by this paper
• C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

  1999cited by this paper
• Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis.

  1999cited by this paper
• C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

  1999cited by this paper
• Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages.

  1999cited by this paper
• Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.

  1999cited by this paper
• Nonfasting Plasma Total Homocysteine Level and Mortality in Middle-Aged and Elderly Men and Women in Jerusalem

  1999cited by this paper
• Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.

  1999cited by this paper
• Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.

  1999cited by this paper
• Clinical efficacy of an automated high-sensitivity C-reactive protein assay.

  1999cited by this paper
• Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study.

  1999cited by this paper
• Urinary albumin excretion. An independent predictor of ischemic heart disease.

  1999cited by this paper
• Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance

  1999cited by this paper
• Elevated C-reactive protein levels in overweight and obese adults.

  1999cited by this paper
• Insulin and risk of cardiovascular disease: a meta-analysis.

  1998cited by this paper
• Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.

  1998cited by this paper
• Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects.

  1998cited by this paper
• Induction of Hyperinsulinemia Combined With Hyperglycemia and Hypertriglyceridemia Increases Plasminogen Activator Inhibitor 1 in Blood in Normal Human Subjects

  1998cited by this paper
• Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

  1998cited by this paper
• Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration.

  1998cited by this paper
• Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.

  1998cited by this paper
• Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

  1998cited by this paper
• Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study.

  1998cited by this paper
• Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats

  1998cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials.

  1997cited by this paper
• A Prospective Study of Coronary Heart Disease in Relation to Fasting Insulin, Glucose, and Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

  1997cited by this paper
• NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X

  1997cited by this paper
• Dose-dependent effects of recombinant human interleukin-6 on glucose regulation.

  1997cited by this paper
• Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients.

  1997cited by this paper
• Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease.

  1996cited by this paper
• Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus.

  1996cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Treatment of mild hyperhomocysteinemia in vascular disease patients.

  1994cited by this paper
• The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life.

  1993cited by this paper
• Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.

  1992cited by this paper
• Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

  1990cited by this paper
• Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions.

  1988cited by this paper
• Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care.

  1984cited by this paper

• Treatment of Tibia Pilon Fractures with the Ilizarov Method

  2019cites this paper
• Regulation of endothelial dynamics by PGC-1α relies on ROS control of VEGF-A signaling.

  2016cites this paper
• Oxidative stress induces loss of pericyte coverage and vascular instability in PGC-1α-deficient mice

  2016cites this paper
• Risk factors for surgical site infection of pilon fractures

  2015cites this paper
• Contemporary Echocardiography In Non-ST Elevation Myocardial Infarction

  2013cites this paper
• Sexual Dysfunction and Cardiovascular Risk – Links and Solutions

  2009cites this paper
• Endothelial Dysfunction, Inflammation, and Exercise

  2009cites this paper
• Metabolic Syndrome and Type 2 Diabetes Mellitus

  2006cites this paper
• Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.

  2006cites this paper
• Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm.

  2005cites this paper
• Is Diabetic Erectile Dysfunction More Difficult to Treat

  2005cites this paper
• Erectile dysfunction: Interrelationship with the metabolic syndrome

  2005cites this paper
• The relationship between levels of alpha1-acid glycoprotein and metabolic parameters of diabetes mellitus.

  2004cites this paper
• Relación de los niveles séricos de Homocisteína con parámetros urinarios del funcionalismo renal en pacientes diabéticos Tipo 2 - Unidad de Diabetes de la Ciudad Hospitalaria "Dr. Enrique Tejera" (CHET).

  2004cites this paper
• Prevention and Treatment of the Metabolic Syndrome

  2004cites this paper